Psoriasiform lesions as a side effect of SGLT-2 therapy
Keywordsflozins, SGLT-2 inhibitors, psoriasis, diabetes, diabetic kidney disease, diabetology, dermatology
SGLT-2 inhibitors (flozins) are one of the new classes of anti-diabetic drugs, used from 2012. They are highly recommended in case of intolerance or contraindication of metformin, but in Poland they are used usually as third-line drug after metformin and sulfonylurea. They growing popularity is caused by their significance in cardiovascular risk reduction and preventive role in according to diabetes complications like chronic kidney disease, or diabetes-induced dementia. The aid of this article is to summarize the knowledge on the risk of psoriasis development in diabetic patients cured with flozins.
In according to the newest studies, flozins may be considered as a pro-psoriatic factor, increasing the risk of this skin disease, especially in patients with diabetic kidney disease. But on the other hand, SGLT-2 inhibitors have significantly decreasing effect on cardiovascular risk, which is increased in psoriatic patients.
Wróbel M, Rokicka D, Strojek K. Flozins — in the light of the latest recommendations. Endokrynol Pol. 2021;72:589–91.
Younis A, Wazni OM. SGLT2 Inhibition and Atrial Fibrillation: Faint Light at the End of the Tunnel. JACC Clin Electrophysiol. 2022;8:1405–6.
Capuano A, Clementi E, Paolisso G. Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis. Front Cardiovasc Med. 2022. doi:10.3389/FCVM.2022.1040649.
Czarkowski M, Raksa K, Powroźniak E, Spozowski K. Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes. Journal of Education, Health and Sport. 2022;12:319–27.
Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules. 2021. doi:10.3390/MOLECULES26237213.
Spozowski K, Powroźniak E, Raksa K, Czarkowski M, Oleksa P. Influence of physical activity, diet, psychic stress and other diseases on psoriaris. Journal of Education, Health and Sport. 2022;12:361–75.
Zucatti KP, Teixeira PP, Wayerbacher LF, Piccoli GF, Correia PE, Fonseca NKO et al. Long-term Effect of Lifestyle Interventions on the Cardiovascular and All-Cause Mortality of Subjects With Prediabetes and Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2022;45:2787–95.
Barros G, Duran P, Vera I, Bermúdez V. Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2022. doi:10.3390/IJMS23147499.
Makrantonaki E, Jiang D, Hossini AM, Nikolakis G, Wlaschek M, Scharffetter-Kochanek K et al. Diabetes mellitus and the skin. Reviews in Endocrine and Metabolic Disorders 2016 17:3. 2016;17:269–82.
Selim S, Lona H, Sikder MdS. Dermatological Manifestations in Diabetes. J Ban Acad Dermatol. 2022;2:22–40.
Rachfal AW, Grant SFA, Schwartz SS. The Diabetes Syndrome – A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms. Int J Gen Med. 2021;14:923.
Holm JG, Thomsen SF. Type 2 diabetes and psoriasis: links and risks. Psoriasis: Targets and Therapy. 2019;9:1–6.
Guo Z, Yang Y, Liao Y, Shi Y, Zhang L. Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity. JID innovations : skin science from molecules to population health. 2021;2:100064.
Kiluk P, Baran A, Kaminski TW, MacIaszek M, Flisiak I. Decreased levels of vaspin and its potential association with cardiometabolic risk in patients with psoriasis: preliminary results. Postepy Dermatol Alergol. 2022;39:307–15.
Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. Diabetes Care. 2016;39:S244–52.
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000–6.
Daiber A, Chlopicki S. Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies. Free Radic Biol Med. 2020;157:15–37.
Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol. 2021. doi:10.1016/J.INTIMP.2021.107492.
Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020. doi:10.1038/S41467-020-15983-6.
Sakaeda T, Kobuchi S, Yoshioka R, Haruna M, Takahata N, Ito Y et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018;15:937.
Chen-Yi W, Ma S-H, Wu C-Y, Lyu Y-S, Chou Y-J, Chang Y-T et al. Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus – a nationwide population-based cohort study. Clin Exp Dermatol. 2022. doi:10.1111/CED.15385.
Boccardi A, Shubrook JH. Cutaneous Reactions to Antidiabetic Agents: A Narrative Review. Diabetology 2022, Vol. 3, Pages 97-107. 2022;3:97–107.
How to Cite
Copyright (c) 2023 Jakub Krzysztof Gałązka, Łukasz Domagalski, Piotr Homa, Zofia Hoffman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Number of views and downloads: 101
Number of citations: 0